Bordeaux, Boston, 5 April 2016 – IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, today announces that it has been granted 510k clearance in the United States and the CE mark in Europe to market its new Jazz Lock® implant.
Jazz Lock® is the first of an innovative range of band products designed for degenerative spine disorder surgery. This new implant expands the JAZZ technological platform and allows Implanet to broaden its activity to the cervical spine, estimated at over $200 million worldwide . Based on the polyester sublaminar braid platform, Jazz Lock® eliminates the mechanism’s locking screw and connecting rod, thanks to a proprietary fastening locking system. Implanet thus offers surgeons a new implant with an optimized and reproducible surgical technique.
Régis Le Couedic, Implanet’s Product Development & Manufacturing Director, says: “Constant innovation is the essential component in maintaining our technological advantage. Over the last two years, we have focused our efforts on finalizing our range of Jazz Band implants, notably with the market’s most extensive range of connectors, to ensure compatibility with all existing posterior fixation systems. A result of collaboration with leading surgeons, Jazz Lock represents a major breakthrough: an innovative, IP protected design offering surgeons a fusion device that no other company currently can.”
Advertisement
Ludovic Lastennet, CEO of Implanet, adds: “Obtaining regulatory clearances to market this new major component of our Jazz Band platform is a significant milestone in terms of product range expansion. Already established in the major spinal deformity segment, we are now accelerating our presence in the degenerative bone disorder segment, which is three times larger. Jazz Lock is the first component of an innovative range of band products for degenerative spine disorder surgery targeted for launch in the near future, in line with our execution plan. Jazz Lock’s commercial launch is underway and further expands the breadth of our product offering.”
Contacts
Florent ALBA NewCap Investor Relations | Strategic Communication 21 Place de la Madeleine – 75008 Paris – France Tel: +33 1 44 71 98 55
